ISV President’s Message
Linda S. Klavinskis, PhD (ISV President, 2024-2025)
Professor of Viral Immunology, Department of Infectious Diseases, King’s College London.
It is an honour and privilege to serve as President of the ISV, an association that brings together talented scientists from across the globe at all stages of their careers to exchange knowledge, sparks new ideas and inspires solutions to the most challenging human, animal, and One Health problems amenable to vaccine and immunotherapeutic interventions.
I would like to thank Dr Denise Doolan, the outgoing ISV President for her leadership during her term and congratulate Ted Gibson on assuming the position of Director of ISV Operations. Read more…
ISV Upcoming Events
Visit ISV’s YouTube Channel to access webinar recordings:
LATEST NEWS
Registration for 2025 ISV Annual Congress Open!
More info…
Abstract Submissions for the 2025 ISV Annual Congress is not Open!
More info…
ISV’s Paper of the Month (POM)
March 2025
AUTHORS
Flitter B, Grecco SN et al.
ISV’s Paper of the Year (POY)
2024
AUTHORS
Mucker EM, Freyn AW, Bixler SL, Cizmeci D, Atyeo C, Earl PL, Natarajan H, Santos G, Frey TR, Levin RH, Meni A, Arunkumar GA, Stadlbauer D, Jorquera PA, Bennett H, Johnson JC, Hardcastle K, Americo JL, Cotter CA, Koehler JW, Davis CI, Shamblin JD, Ostrowski K, Raymond JL, Ricks KM, Carfi A, Yu WH, Sullivan NJ, Moss B, Alter G, Hooper JW.
ISV Mini-Symposium
Thursday, April 24th
Speakers & Titles:
- Global Lifelong Burden of RSV – Louis Bont, M.D., Ph.D, Professor, University Medical Center Utrecht
- Prefusion-F Stability and Vaccine Efficacy: Structure-Based Vaccines for RSV/HMPV/PIV – Peter Kwong, Ph.D, Richard J. Stock Professor, Biochemistry and Molecular Biophysics Columbia University
- PIV5-vectored RSV Intranasal Vaccine (BLB201) is Safe and Immunogenic in Healthy Adults and Young Children, Hong Jin, Ph.D, Chief Scientific Officer, CynVac/Blue Lake Bio
- RSVPreF Vaccine in Older Adults and At-Risk Adults Aged 18 – 59 Years – Kumar Ilangovan, MD, MSPH, MMCi, FACP, FAAP, Director, Vaccines Clinical Research & Global Clinical Lead, RSV Adult Vaccine Program, Pfizer Vaccines
ISV Webinar Series
Wednesday, April 30th
Title: Safety and immunogenicity of the live-attenuated candidate vaccine ‘hRVFV-4s’ against Rift Valley fever in healthy adults
Speaker: P.J. (Paul) Wichgers Schreur, Wageningen Bioveterinary Research, Netherlands
ISV Annual Supporters
